Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Infection
Published in: Infection 5/2011

01-10-2011 | Case Report

Yokenella regensburgei in an immunocompromised host: a case report and review of the literature

Authors: Y.-C. Lo, Y.-W. Chuang, Y.-H. Lin

Published in: Infection | Issue 5/2011

Login to get access

Abstract

Yokenella regensburgei belongs to the Enterobacteriaceae and shares some biochemical characteristics with Hafnia alvei. A few case reports have suggested that it is an opportunistic pathogen, but there is no strong evidence to support its clinical importance. Until recently, it was difficult to accurately differentiate between Y. regensburgei and H. alvei by use of routine identification techniques. Here, we present a case of soft tissue infection and bacteremia caused by Y. regensburgei, which was successfully treated by intravenous administration of ceftriaxone for three weeks, and review the previous literature.
Literature
1.
Stock I, Sherwood KJ, Wiedemann B. Antimicrobial susceptibility patterns, beta-lactamases, and biochemical identification of Yokenella regensburgei strains. Diagn Microbiol Infect Dis. 2004;48:5–15.PubMedCrossRef
2.
Abbott SL, Janda JM. Isolation of Yokenella regensburgei (“Koserella trabulsii”) from a patient with transient bacteremia and from a patient with a septic knee. J Clin Microbiol. 1994;32:2854–5.PubMed
3.
Steigerwalt AG, Fanning GR, Fife-Asbury MA, Brenner DJ. DNA relatedness among species of Enterobacter and Serratia. Can J Microbiol. 1976;22:121–37.PubMedCrossRef
4.
Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA. Manual of clinical microbiology. 9th ed. ASM Press; 2007. pp 653–5.
5.
Hickman-Brenner FW, Huntley-Carter GP, Fanning GR, Brenner DJ, Farmer JJ 3rd. Koserella trabulsii, a new genus and species of Enterobacteriaceae formerly known as Enteric Group 45. J Clin Microbiol. 1985;21:39–42.PubMed
6.
Kosako Y, Sakazaki R, Yoshizaki E. Yokenella regensburgei gen. nov., sp. nov.: a new genus and species in the family Enterobacteriaceae. Jpn J Med Sci Biol. 1984;37:117–24.PubMed
7.
Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing; 20th informational supplement (June 2010 update). Document M100-S20-U. Wayne: CLSI; 2010.
8.
Kosako Y, Sakazaki R, Huntley-Carter GP, Farmer JJ III. Yokenella regensburgei and Koserella trabulsii are subjective synonyms. Int J Syst Bacteriol. 1987;37:127–9.CrossRef
9.
Fajardo Olivares M, Blanco Palenciano J, Marquez Laffon I, Ruiz Leon JM. Yokenella regensburgei infection in a perimalleolar ulcer. Med Clin (Barc). 2005;125:358–9.CrossRef
Metadata
Title
Yokenella regensburgei in an immunocompromised host: a case report and review of the literature
Authors
Y.-C. Lo
Y.-W. Chuang
Y.-H. Lin
Publication date
01-10-2011
Publisher
Springer-Verlag
Published in
Infection / Issue 5/2011
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-011-0139-z

Other articles of this Issue 5/2011

Infection 5/2011 Go to the issue

Clinical and Epidemiological Study

Outcomes of post-cataract surgery endophthalmitis referred to a tertiary center from local hospitals in the south of China

Clinical and Epidemiological Study

Risk of liver-associated morbidity and mortality in a cohort of HIV and HBV coinfected Han Chinese

Clinical and Epidemiological Study

Natural leukocyte interferon alpha (Alfaferone) combined with ribavirin in the treatment of patients with HCV-related cirrhosis: our experience

Brief Report

Clostridium difficile infection: monoclonal or polyclonal genesis?

Case Report

Legionellosis must be kept in mind in case of pneumonia with lung abscesses in children receiving therapeutic steroids

Solicited Commentary

Immunogenicity of two different hepatitis B vaccine schedules
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits